SNMMI In The News

February 1, 2013

Amyvid backers respond to MEDCAC meeting

DOTMed Business News

Despite a lack of support from an advisory panel, backers of the PET amyloid imaging drug Amyvid are urging the Centers for Medicare and Medicaid Services to evaluate the evidence and provide coverage for the U.S. Food and Drug Administration-approved indication.

Related Items